Takagi T, Sakai C, Oguro M
Division of Hematology-Chemotherapy, Chiba Cancer Center Hospital.
Gan To Kagaku Ryoho. 1993 Nov;20(14):2191-4.
Twenty-one patients with advanced-stage, intermediate- and high-grade non-Hodgkin's lymphomas were treated with alternating CHOP-MEVP chemotherapy. CHOP therapy consisted of CPA 650 mg/m2, ADM 45 mg/m2, VCR 1.4 mg/m2 and Pred 40 mg/m2 (po). MEVP therapy consisted of MIT 10 mg/m2 (iv) VDS 2 mg/m2 (iv) on day 1, etoposide 200 mg/m2 (po) on days 1-3, and Pred 40 mg/m2 (po) on days 1-5. Three courses of CHOP therapy and MEVP therapy were alternatively administered every three weeks. CR was achieved in 15 (71.4%) of 21 patients. Survival rate and relapse-free rate at 2 years for all 21 patients were 61.9% and 30.9%, respectively. Toxicity was generally tolerable except for CMV interstitial pneumonitis in a patient with IBL-like T-cell lymphoma and secondary leukemia in a patient with T-cell lymphoma. Chemotherapy of higher dose intensity is required to improve the relapse-free survival rate in these subsets of lymphoma.
21例晚期中、高度非霍奇金淋巴瘤患者接受了CHOP-MEVP交替化疗。CHOP方案包括环磷酰胺650mg/m²、阿霉素45mg/m²、长春新碱1.4mg/m²及强的松40mg/m²（口服）。MEVP方案包括第1天米托蒽醌10mg/m²（静脉注射）、长春地辛2mg/m²（静脉注射），第1 - 3天依托泊苷200mg/m²（口服），第1 - 5天强的松40mg/m²（口服）。每三周交替给予三个疗程的CHOP方案和MEVP方案。21例患者中有15例（71.4%）达到完全缓解。21例患者的2年生存率和无复发生存率分别为61.9%和30.9%。除1例免疫母细胞样T细胞淋巴瘤患者发生巨细胞病毒性间质性肺炎和1例T细胞淋巴瘤患者发生继发性白血病外，毒性反应一般可耐受。需要更高剂量强度的化疗来提高这些淋巴瘤亚组的无复发生存率。
